Literature DB >> 11177730

Clinical Trials Report.

Richard D. Pearson1.   

Abstract

Year:  2001        PMID: 11177730     DOI: 10.1007/s11908-001-0058-8

Source DB:  PubMed          Journal:  Curr Infect Dis Rep        ISSN: 1523-3847            Impact factor:   3.725


× No keyword cloud information.
  6 in total

1.  Safety and efficacy of atovaquone and proguanil hydrochloride for the prophylaxis of Plasmodium falciparum malaria in South Africa.

Authors:  J D van der Berg; C S Duvenage; N S Roskell; T R Scott
Journal:  Clin Ther       Date:  1999-04       Impact factor: 3.393

2.  A randomized, double-blind, placebo-controlled field trial to determine the efficacy and safety of Malarone (atovaquone/proguanil) for the prophylaxis of malaria in Zambia.

Authors:  T Y Sukwa; M Mulenga; N Chisdaka; N S Roskell; T R Scott
Journal:  Am J Trop Med Hyg       Date:  1999-04       Impact factor: 2.345

3.  Prophylactic activity of atovaquone against Plasmodium falciparum in humans.

Authors:  T A Shapiro; C D Ranasinha; N Kumar; P Barditch-Crovo
Journal:  Am J Trop Med Hyg       Date:  1999-05       Impact factor: 2.345

Review 4.  Malarone (atovaquone and proguanil hydrochloride): a review of its clinical development for treatment of malaria. Malarone Clinical Trials Study Group.

Authors:  S Looareesuwan; J D Chulay; C J Canfield; D B Hutchinson
Journal:  Am J Trop Med Hyg       Date:  1999-04       Impact factor: 2.345

5.  Randomised placebo-controlled study of atovaquone plus proguanil for malaria prophylaxis in children.

Authors:  B Lell; D Luckner; M Ndjavé; T Scott; P G Kremsner
Journal:  Lancet       Date:  1998-03-07       Impact factor: 79.321

6.  Efficacy and safety of atovaquone/proguanil as suppressive prophylaxis for Plasmodium falciparum malaria.

Authors:  G D Shanks; D M Gordon; F W Klotz; G M Aleman; A J Oloo; D Sadie; T R Scott
Journal:  Clin Infect Dis       Date:  1998-09       Impact factor: 9.079

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.